Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib + ICI in FGFR-altered advanced solid tumors
NCT06551896Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Aug 2024
- Primary completion
- Jul 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
01
Overview
A Phase 2 trial of pemigatinib in solid tumor (advanced stage), sponsored by Sun Yat-sen Memorial Hospital. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
pemigatinib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06551896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06551896.